The antibody–drug conjugate trastuzumab deruxtecan is being investigated in the DESTINY-Breast trials for the treatment of breast cancer.
24-03-2025 | Breast Cancer | Clinical Trial Summary | Article
24-03-2025 | Breast Cancer | Clinical Trial Summary | Article
The antibody–drug conjugate trastuzumab deruxtecan is being investigated in the DESTINY-Breast trials for the treatment of breast cancer.